Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alprostadil, Sodium Ferulate, and Dopamine in Pediatric AKI
NCT03892447Phase 4Unknown
- Sponsor
- Shengjing Hospital of China Medical University
- Start
- Aug 2019
- Primary completion
- Apr 2021
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of Alprostadil Liposomes for Injection in acute kidney injury (AKI) (3 arms), sponsored by Shengjing Hospital of China Medical University. Primary endpoints: Change in Serum Creatinine at 52 weeks, Estimated Glomerular Filtration Rate at 52 weeks and 1 more. Status: unknown.
02
Drugs
Alprostadil Liposomes for Injection
03
Conditions
acute kidney injury (AKI)
Beyond the preview
Go deeper on NCT03892447.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03892447.